Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zevalin +/- Motexafin Gadolinium in Refractory NHL
NCT01549886Phase 2Terminated
- Sponsor
- Spectrum Pharmaceuticals, Inc.
- Start
- Nov 2011
- Primary completion
- Jun 2014
- Modality
- Orthosteric Ligands, Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of motexafin gadolinium in Non-Hodgkin lymphoma (NHL), sponsored by Spectrum Pharmaceuticals, Inc.. Started Nov 2011; status: terminated.
02
Drugs
motexafin gadolinium
03
Conditions
Non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT01549886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01549886.